Listen
TEVIMBRA (tislelizumab) - Oesophageal squamous cell carcinoma
Opinions on drugs -
Posted on
Nov 21 2024
- Updated on
Aug 06 2025
Reason for request
First listing
Summary of opinion
Unfavourable opinion for reimbursement in the indication “TEVIMBRA as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (OSCC) after prior platinum-based chemotherapy”
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of TEVIMBRA (tislelizumab) 100 mg concentrate for solution for infusion is insufficient in the MA indication to justify public funding. |
Clinical Added Value
| Not applicable |
Documents
English version
Contact Us
Évaluation des médicaments
